<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0906222166
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOVOEIGHT 250 IU Powder & Solvent For Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TUROCTOCOG ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        574.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NovoEight<sup>&reg;</sup> contains the active substance turoctocog alfa, human coagulation factor VIII. Factor VIII is a protein naturally found in the blood that helps it to clot.</p><p>&nbsp;</p><p>NovoEight<sup>&reg;</sup> is used to treat and prevent bleeding episodes in patients with haemophilia A (inborn factor VIII deficiency) and can be used for all age groups.</p><p>In patients with haemophilia A, factor VIII is missing or not working properly. NovoEight<sup>&reg;</sup> replaces this faulty or missing &lsquo;factor VIII&rsquo; and helps blood to form clots at the site of bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use NovoEight<sup>&reg;</sup>:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hamster proteins.</p><p>&nbsp;</p><p>Do not use NovoEight<sup>&reg;</sup> if either of the above applies to you. If you are not sure, talk to your doctor before using this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before using NovoEight<sup>&reg;</sup>.</p><p>&nbsp;</p><p>There is a rare chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to NovoEight<sup>&reg;</sup>. Early signs of allergic reactions are rash, hives, weals, generalised itching, swelling of lips and tongue, difficulty in breathing, wheezing, tightness of the chest, general feeling of being unwell, and dizziness.</p><p>&nbsp;</p><p>If any of these symptoms occur, stop the injection immediately and contact your doctor.</p><p>&nbsp;</p><p>Talk to your doctor if you think that your bleed is not being controlled with the dose you receive, as there can be several reasons for this. Some people using this medicine can develop antibodies to factor VIII (also known as factor VIII inhibitors). Factor VIII inhibitors make NovoEight<sup>&reg;</sup> less effective in preventing or controlling bleeding. If this happens, you may need a higher dose of NovoEight<sup>&reg;</sup> or a different medicine to control your bleed. Do not increase the total dose of NovoEight<sup>&reg;</sup> to control your bleed without talking to your doctor. You should tell your doctor if you have been previously treated with factor VIII products, especially if you developed inhibitors, since there might be a higher risk that it happens again.</p><p>&nbsp;</p><p>The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all Factor VIII medicines. These inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. If you or your child&acute;s bleeding is not being controlled with NovoEight<sup>&reg;</sup>, tell your doctor immediately.</p><p>&nbsp;</p><p><strong>Other medicines and NovoEight<sup>&reg;</sup></strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breastfeeding </strong></p><p>If you are pregnant or breastfeeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>NovoEight<sup>&reg;</sup> has no influence on your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>NovoEight<sup>&reg;</sup> contains sodium </strong></p><p>This medicine contains 30.5&nbsp;mg sodium (main component of cooking/table salt) per reconstituted vial.</p><p>This is equivalent to 1.5% of the recommended maximum dietary intake of sodium for an adult.</p><p>Talk to your doctor if you are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Treatment with NovoEight<sup>&reg;</sup> will be started by a doctor who is experienced in the care of patients with haemophilia A. Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Your doctor will calculate your dose for you. This will depend on your weight and what the medicine is being used for.</p><p>&nbsp;</p><p><strong>Prevention of bleeding</strong></p><p>The usual dose of NovoEight<sup>&reg;</sup> is 20 to 50 international units (IU) per kg of body weight. The injection is given every 2 to 3 days. In some cases, especially in younger patients, more frequent injections or higher doses may be needed.</p><p>&nbsp;</p><p><strong>Treatment of bleeding</strong></p><p>The dose of NovoEight<sup>&reg;</sup> is calculated depending on your body weight and the factor VIII levels to be achieved. The target factor VIII levels will depend on the severity and location of the bleeding.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>NovoEight<sup>&reg;</sup> can be used in children of all ages. In children (below the age of 12) higher doses or more frequent injections may be needed. Adolescents (above the age of 12) can use the same dose as adults.</p><p><strong>&nbsp;</strong></p><p><strong>How NovoEight<sup>&reg;</sup> is given</strong></p><p>NovoEight<sup>&reg;</sup> is given as an injection into a vein. See &lsquo;Instructions on how to use NovoEight<sup>&reg;</sup>&rsquo; for more information.</p><p><u>&nbsp;</u></p><p><strong>If you use more NovoEight<sup>&reg;</sup> than you should</strong></p><p>If you use more NovoEight<sup>&reg;</sup> than you should, tell your doctor or go to a hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use NovoEight<sup>&reg;</sup></strong></p><p>You should contact your doctor if you have missed a dose and do not know how to compensate for this.</p><p>&nbsp;</p><p><strong>If you stop using NovoEight<sup>&reg;</sup></strong></p><p>If you stop using NovoEight<sup>&reg;</sup>, you may no longer be protected against bleeding or a current bleed may not stop. Do not stop using NovoEight<sup>&reg; </sup>without talking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with this medicine.</p><p>&nbsp;</p><p>If severe, sudden allergic reactions (anaphylactic reactions) occur (very rare), the injection must be stopped immediately. You must contact your doctor immediately if you have one of the following early symptoms:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing, shortness of breath or wheezing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the lips and tongue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, hives, weals or generalised itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy or loss of consciousness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (having pale and cold skin, fast heartbeat).</p><p>&nbsp;</p><p>Severe symptoms, including difficulty in swallowing or breathing and red or swollen face or hands, require prompt emergency treatment.</p><p>&nbsp;</p><p>If you have a severe allergic reaction, your doctor may change your medicine.</p><p><strong>&nbsp;</strong></p><p>For children not previously treated with Factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients); however patients who have received previous treatment with Factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients). If this happens to you or your child&acute;s medicines may stop working properly and you or your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing changes in the way the liver functions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactions (redness and itching) around the site where you injected the medicine.</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) in patients who have not previously been treated with Factor VIII medicines</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blushing of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of vein</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into joint spaces</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in muscle tissue</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness around the site where you placed catheter</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting.</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (insomnia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling hot</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness of muscles</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in muscles</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in legs and arms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of legs and feet</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack.</p><p>&nbsp;</p><p><strong>Side effects in children and adolescents</strong></p><p>The side effects observed in children and adolescents are the same as observed in adults.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated after &lsquo;Expiry&rsquo; on the carton and on the vial and the pre-filled syringe labels. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Before the NovoEight<sup>&reg;</sup> powder is reconstituted it may be kept at:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; room temperature (&le; 30&deg;C) for a single period no longer than 9 months</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; above room temperature (30&deg;C up to 40&deg;C) for a single period no longer than 3 months.</p><p>&nbsp;</p><p>Once the product has been taken out of the refrigerator, the product must not be returned to the refrigerator.</p><p>&nbsp;</p><p>Please record the beginning of storage and the storage temperature on the product carton.</p><p>&nbsp;</p><p>Once you have reconstituted NovoEight<sup>&reg;</sup> it should be used right away. If you cannot use the reconstituted NovoEight<sup>&reg;</sup> solution immediately, it should be used within:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 hours stored at 2&deg;C &ndash; 8&deg;C</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hours stored at &le; 30&deg;C, for product which has been kept for a single period no longer than 9 months at room temperature (&le; 30&deg;C)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 hours stored up to 40&deg;C, for product which has been kept for a single period no longer than 3 months at above room temperature (30&deg;C up to 40&deg;C).</p><p>&nbsp;</p><p>Store the reconstituted product in the vial. If not used straight away the medicine may no longer be sterile and could cause infection. Do not store the solution without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p>The powder in the vial appears as a white or slightly yellow powder. Do not use the powder if the colour has changed.</p><p>&nbsp;</p><p>The reconstituted solution will be clear to slightly opalescent. Do not use this medicine if you notice that it is cloudy or contains visible particles.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is turoctocog alfa (human coagulation factor VIII (rDNA)). Each vial of NovoEight<sup>&reg;</sup> contains nominally 250, 500 or&nbsp;1000&nbsp;IU turoctocog alfa.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are L-histidine, sucrose, polysorbate 80, sodium chloride, L-methionine, calcium chloride dihydrate, sodium hydroxide and hydrochloric acid.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The ingredients in the solvent are sodium chloride and water for injections.</p><p>&nbsp;</p><p>After reconstitution with the supplied solvent (sodium chloride 9 mg/ml (0.9%) solution for injection), the prepared solution for injection contains 62.5, 125 or&nbsp;250&nbsp;IU turoctocog alfa per ml, respectively, (based on the strength of turoctocog alfa, i.e. 250, 500 or 1000&nbsp;IU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NovoEight® is a powder and solvent for solution for injection.
Each pack of NovoEight® contains a vial with white or slightly yellow powder, a 4 ml pre-filled syringe with a clear colourless solution, a plunger rod and a vial adapter. 



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء نوفو ايت<sup>&trade;</sup> على المادة الفعالة توركتوكوج ألفا (Turoctocog Alfa)، وهي عبارة عن عامل التخثر الثامن البشري. العامل الثامن هو بروتين موجود طبيعياً في الدم والذي يساعد على تخثر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم استخدام دواء نوفو ايت<sup>&trade;</sup> لعلاج ومنع نوبات النزيف التي تحدث للمرضى المصابين بمرض الهيموفيليا أ (نقص وراثي في عامل التخثر الثامن)، ويمكن استخدامه لكل المراحل العمرية.</p><p dir="RTL">يعاني مرضى &quot;الهيموفيليا أ&quot; من عدم وجود العامل الثامن لتخثر الدم أو من عدم أدائه لوظائفه كما ينبغي. يعمل دواء نوفو ايت<sup>&trade;</sup> على تعويض وإحلال محل هذا &quot;العامل الثامن&quot; غير الموجود أو الذي به خلل، ويساعد الدم على تكوين تخثرات في موضع النزف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استخدام نوفو ايت</strong><sup>&trade;</sup><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من المادة الفعالة أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من بروتينات الجرذ الأرنبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم دواء نوفو ايت<sup>&trade;</sup> إذا كانت أيٌ من الحالات أعلاه تنطبق عليك. إذا لم تكن متأكداً، فاستشر طبيبك قبل استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">ينبغي استشارة الطبيب قبل استعمال دواء نوفو ايت<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك احتمالية نادرة لحدوث تفاعل تأقي (رد فعل تحسسي مفاجئ وشديد) نتيجة لاستعمال نوفو ايت<sup>&trade;</sup>. ومن العلامات المبكرة لرد الفعل التحسسي هي حدوث طفح جلدي وشرى وانتبار وحكة عامة وتورم في الشفاه واللسان وصعوبة في التنفس وأزيز وضيق في الصدر وشعور عام بعدم الارتياح ودوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة حدوث أي من هذه الأعراض، توقف عن الحقن في الحال واتصل بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك إذا لم تجد تحسناً في السيطرة على النزيف بالجرعة التي تتلقاها، حيث قد يرجع ذلك إلى أسباب عديدة. من الممكن أن يتطور لدى بعض الأشخاص، الذين يستخدمون هذا الدواء، أجسام مضادة للعامل الثامن (والمعروفة أيضاً باسم مثبطات العامل الثامن). يؤدي وجود مثبطات العامل الثامن هذه إلى تقليل فعالية دواء نوفو ايت<sup>&trade;</sup> في منع حدوث النزيف أو السيطرة عليه. وفي حالة حدوث ذلك، فقد تحتاج إلى استخدام جرعة أعلى من دواء نوفو ايت<sup>&trade;</sup> أو استخدام دواء مختلف للسيطرة على النزيف. لا تقم بزيادة الجرعة الإجمالية لدواء نوفو ايت<sup>&trade;</sup> من أجل السيطرة على النزيف بدون استشارة الطبيب. يجب إخبار طبيبك إذا كنت قد تلقيت علاجاً مسبقاً بمنتجات العامل الثامن، خاصةً في حالة ظهور مثبطات لديك، حيث قد ترتفع مخاطر حدوث ذلك مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تكوُّن المثبطات (الأجسام المضادة) يعتبر من المضاعفات المعروفة التي يمكن أن تحدث أثناء العلاج بجميع أدوية العامل الثامن. وهذه المثبطات، وخاصةً عند وجودها بمستويات عالية، تمنع سير العلاج بالشكل الصحيح، ولهذا، ستتم مراقبة حالتك أو حالة طفلك بعناية لمتابعة تطور هذه المثبطات. وإذا لم يتم التحكم في النزيف لديك أو لدى طفلك باستخدام نوفو ايت<sup>&trade;</sup>، أخبر طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونوفو ايت</strong><sup>&trade;</sup></p><p dir="RTL">أخبر الطبيب إذا كنت تتناول أدوية أخرى أو تناولت أيه أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية، أو إذا كنتِ تظنين أنكِ حامل أو تنوين الحمل، فاستشيري طبيبك قبل استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يوجد تأثير لدواء نوفو ايت<sup>&trade;</sup> على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي دواء نوفو ايت</strong><sup>&trade;</sup><strong> على صوديوم </strong></p><p dir="RTL">يحتوي هذا الدواء على 30.5 ملجم من الصوديوم (المكون الرئيسي لملح المائدة/ملح الطعام) لكل قارورة ممزوجة.</p><p dir="RTL">وهذا يعادل 1.5% من الحد الأقصى الموصى به من تناول الصوديوم للبالغين.</p><p dir="RTL">تحدث إلى طبيبك إذا كنت تتبع نظاماً غذائياً للتحكم في الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يبدأ العلاج بدواء نوفو ايت<sup>&trade;</sup> من قِبل طبيب ذي خبرة في علاج مرض &quot;الهيموفيليا أ&quot;. التزم دائماً باستخدام هذا الدواء بالطريقة التي يصفها لك الطبيب. ويجب استشارة الطبيب في حالة الشك بشأن طريقة استعماله على الوجه الصحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يقوم الطبيب باحتساب الجرعة التي تناسبك. ويعتمد ذلك على وزنك ودواعي استعمال الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>منع النزيف</strong></p><p dir="RTL">تعد الجرعة المعتادة لدواء نوفو ايت<sup>&trade;</sup> هي 20 حتى 50 وحدة دولية (IU) لكل كجم من وزن الجسم. ويتم استعمال الحقن كل يومين أو ثلاثة أيام. في بعض الحالات، خاصةً لدى المرضى الأصغر سناً، قد يستلزم استعمال معدل تكرار أكثر للحقن أو جرعات أعلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج النزيف</strong></p><p dir="RTL">يتم احتساب جرعة نوفو ايت<sup>&trade;</sup> وفقاً لوزن الجسم ومستويات عامل التخثر الثامن المطلوب تحقيقها. وتعتمد المستويات المستهدفة لعامل التخثر الثامن على خطورة النزيف وموضعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استعماله للأطفال والمراهقين</strong></p><p dir="RTL">يمكن استخدام دواء نوفو ايت<sup>&trade;</sup> للأطفال في جميع الأعمار. بالنسبة للأطفال (الأصغر عن 12 عاماً)، قد يستلزم استخدام جرعات أعلى أو معدل تكرار أكثر لعمليات الحقن. &rlm;‫وبالنسبة للمراهقين (الأكبر من 12 عاماً)، فيمكن استخدام نفس جرعات البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء دواء نوفو ايت</strong><sup>&trade;</sup></p><p dir="RTL">يؤخذ دواء نوفو ايت<sup>&trade;</sup> كحقنة في الوريد. انظر &quot;تعليمات عن كيفية استعمال نوفو ايت<sup>&trade;</sup>&quot; للحصول على مزيد من المعلومات.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>في حالة استخدام جرعة زائدة من نوفو ايت</strong><sup>&trade;</sup><strong> عن الجرعة الموصوفة</strong></p><p dir="RTL">في حالة استخدام جرعة زائدة من نوفو ايت<sup>&trade;</sup> عن الجرعة الموصوفة، ينبغي استشارة الطبيب أو الذهاب إلى المستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة نوفو ايت</strong><sup>&trade;</sup></p><p dir="RTL">يجب الاتصال بالطبيب في حالة نسيان جرعة من الدواء وعدم معرفة كيفية تعويضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء نوفو ايت</strong><sup>&trade;</sup></p><p dir="RTL">في حالة التوقف عن استخدام دواء نوفو ايت<sup>&trade;</sup>، فأنت لم تعد في حماية ضد حدوث نزيف أو قد لا يتوقف النزيف الحالي. لا تتوقف عن استخدام دواء نوفو ايت<sup>&trade;</sup> بدون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أيه أسئلة أخرى حول استعمال هذا الدواء، فيمكنك سؤال الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه. قد تحدث الآثار الجانبية التالية مع استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة حدوث رد فعل تحسسي مفاجئ وحاد (التفاعلات التأقية) (أمر نادر جداً)، يجب التوقف عن الحقن فوراً. يجب استشارة طبيبك فوراً إذا حدثت لك أي من الأعراض المبكرة التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أو ضيق النفس أو أزيز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الشفتين أو اللسان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو شرى أو انتبار أو حكة عامة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار أو فقدان الوعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (شحوب وبرودة في الجلد، سرعة ضربات القلب)</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك أعراض حادة، تشمل صعوبة البلع أو التنفس واحمرار أو تورم الوجه أو اليدين، والتي تتطلب العلاج الطارئ الفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث لك رد فعل تحسسي شديد، قد يقوم طبيبك بتغيير الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للأطفال الذين لم يتلقوا علاجاً فيما سبق بأدوية العامل الثامن، قد تتكون الأجسام المضادة المثبطة (انظر القسم 2) بشكل شائع جداً (أكثر من مريض واحد من كل 10 مرضى)، بينما بالنسبة للمرضى الذين تلقوا علاجاً فيما سبق بالعامل الثامن (أكثر من 150 يوماً من العلاج)، من غير الشائع أن يتعرضوا لهذه المخاطر (بنسبة أقل من مريض واحد من كل 100 مريض). وإذا حدث هذا لك أو لطفلك، قد لا تعمل الأدوية بشكل صحيح وقد تعاني أو يعاني طفلك من نزيف مستمر. وإذا حدث هذا، يجب الاتصال بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تصيب حتى شخص واحد من بين </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور تغيرات في وظائف الكبد بعد إجراءات اختبارات الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات (احمرار وحكة) حول موضع حقن الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تصيب حتى شخص واحد من بين 10 أشخاص) في المرضى الذين لم يتلقوا علاجاً فيما سبق بأدوية العامل الثامن</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار البشرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وريدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل المسافات البينية للمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأنسجة العضلية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار حول موضع تثبيت القسطرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تصيب حتى شخص واحد من بين </strong><strong>100</strong><strong> شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالسخونة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الساقين والذراعين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الساقين والقدمين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية لدى الأطفال والمراهقين</strong></p><p dir="RTL">تعد الآثار الجانبية الملاحظة لدى الأطفال والمراهقين هي نفس الآثار الجانبية التي تمت ملاحظتها في البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&rlm;‫الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&rlm;‫في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الصيدلي أو الممرض. &rlm;‫يشمل هذا أيه آثار جانبية محتملة غير واردة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون بعد كلمة &quot;Expiry&quot; على العبوة الكرتونية وعلى القنينة وعلى ملصقات الحُقن المعبأة مسبقاً. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في الثلاجة (في درجة حرارة 2 - 8 درجات مئوية).</p><p dir="RTL">يُراعى عدم التجميد.</p><p dir="RTL">&rlm;‫تُحفظ القنينة في عبوة الكرتون الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل مزج مسحوق نوفو ايت<sup>&trade;</sup>، يمكن حفظه في:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة حرارة الغرفة (أقل من أو تساوي 30 درجة مئوية) لفترة واحدة لا تزيد عن 9 أشهر</p><p dir="RTL"><strong>أو</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلى من درجة حرارة الغرفة (من 30 إلى 40 درجة مئوية) لفترة واحدة لا تزيد عن 3 أشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد إخراج المنتج من الثلاجة، يجب عدم إعادة المنتج إلى الثلاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى تدوين تاريخ بداية التخزين ودرجة حرارة التخزين على العبوة الكرتونية للمنتج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد مزج محلول نوفو ايت<sup>&trade;</sup>، يجب استخدامه في الحال. وفي حالة عدم التمكن من استخدام محلول نوفو ايت<sup>&trade;</sup> الممزوج على الفور، يجب استخدامه خلال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24 ساعة عند تخزينه في درجة حرارة تتراوح ما بين 2 - 8 درجات مئوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ساعات عند تخزينه في درجة حرارة أقل من أو تساوي 30 درجة مئوية، بالنسبة للمنتج الذي تم تخزينه لفترة واحدة لا تزيد عن 9 أشهر في درجة حرارة الغرفة (أقل من أو تساوي 30 درجة مئوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ساعات عند تخزينه في درجة حرارة تصل إلى 40 درجة مئوية، بالنسبة للمنتج الذي تم تخزينه لفترة واحدة لا تزيد عن 3 أشهر في درجة حرارة أعلى من درجة حرارة الغرفة (من 30 حتى 40 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بحفظ المنتج الممزوج في القنينة. وفي حالة عدم استخدامه بشكل فوري، قد يصبح الدواء غير معقم وقد يتسبب في حدوث عدوى. لا تقم بتخزين المحلول بدون نصيحة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يظهر المسحوق الموجود في القنينة كمسحوق أبيض أو خفيف الاصفرار. لا تستخدم المسحوق إذا تغير لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيكون المحلول الممزوج صافياً أو غميماً بشكل طفيف. لا تستخدم هذا الدواء إذا لاحظت أنه عكر أو يحتوي على جزيئيات مرئية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أيه أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعد المادة الفعالة هي توركتوكوج ألفا (عامل التخثر الثامن البشري (rDNA)). تحتوي كل قنينة من نوفو ايت<sup>&trade;</sup> اعتبارياً على 250 أو 500 أو 1000&nbsp;وحدة دولية من التوركتوكوج ألفا.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتشكل المكونات الأخرى من إل-هيستيدين وسكروز وبوليسوربات 80 وكلوريد الصوديوم وإل-ميثيونين وكلوريد كالسيوم ثنائي الهيدرات وهيدروكسيد الصوديوم وحمض الهيدروكلوريك.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكونات المذيب هي كلوريد الصوديوم وماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد المزج بالمذيب الملحق (محلول للحقن من كلوريد الصوديوم 9 ملجم/مل (0.9%))، سوف يحتوي محلول الحقن الذي تم تحضيره على 62.5 أو 125 أو 250 وحدة دولية من التوركتوكوج ألفا لكل مل بالترتيب، (وفقاً لقوة التوركتوكوج ألفا، أي 250 أو 500 أو 1000&nbsp;وحدة دولية).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نوفو ايت<sup>&trade;</sup> هو مسحوق ومذيب لمحلول الحقن.</p><p dir="RTL">تحتوي كل عبوة من نوفو ايت<sup>&trade;</sup> على قنينة بها مسحوق أبيض أو خفيف الاصفرار، وحقنة معبأة مسبقاً 4 مل تحتوي على محلول صافٍ عديم اللون، وذراع كبّاس ومهايئ للقنينة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر / 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
250 IU powder and solvent for solution for injection
500 IU powder and solvent for solution for injection
1000 IU powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each powder vial contains nominally 250, 500, 1000 IU human coagulation factor VIII (rDNA), turoctocog alfa.

After reconstitution NovoEight® contains approximately 62.5, 125 or 250 IU/ml of human coagulation factor VIII (rDNA), turoctocog alfa. 

The potency (IU) is determined using the European Pharmacopoeia (Ph. Eur) chromogenic assay. The specific activity of NovoEight® is approximately 8,300 IU/mg protein.

Turoctocog alfa (human coagulation factor VIII (rDNA)) is a purified protein that has 1,445 amino acids with an approximate molecular mass of 166 kDA. It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells, and prepared without the addition of any human or animal derived protein in the cell culture process, purification or final formulation.

Turoctocog alfa is a B-domain truncated recombinant human coagulation factor VIII (B-domain consists of 21 amino acids of the wild type B-domain) without any other modifications in the amino acid sequence.

Excipient with known effect
The medicinal product contains 30.5 mg sodium per reconstituted vial.
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.

White or slightly yellow powder or friable mass. 

Clear and colourless solution for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).</p><p>&nbsp;</p><p>NovoEight<sup>&reg;</sup> can be used for all age groups.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be under the supervision of a doctor experienced in the treatment of haemophilia.</p><p><u>&nbsp;</u></p><p><u>Treatment monitoring</u></p><p>During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients. In a single dose pharmacokinetic study in adult patients the maximum exposure (C<sub>max</sub>) and the total exposure (AUC) increased with increasing body mass index (BMI) indicating that dose adjustments may be required. An increase in dose may be required for underweight patients (BMI &lt;18.5&nbsp;kg/m<sup>2</sup>) and a decrease in dose may be required for obese patients (BMI &ge;30&nbsp;kg/m<sup>2</sup>), but there is insufficient data to recommend specific dose adjustments, see section 5.2.</p><p>&nbsp;</p><p>In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable.</p><p>&nbsp;</p><p>When using an <em>in vitro</em> thromboplastin time (aPTT)-based one stage clotting assay for determining factor VIII activity in patients&rsquo; blood samples, plasma factor VIII activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay. Also there can be significant discrepancies between assay results obtained by aPTT-based one stage clotting assay and the chromogenic assay according to Ph. Eur. This is of importance particularly when changing the laboratory and/or reagents used in the assay.</p><p>&nbsp;</p><p><strong>Posology</strong></p><p>The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and the patient&rsquo;s clinical condition.</p><p>&nbsp;</p><p>The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. The activity of factor VIII in plasma is expressed either as percentage (relative to normal level human plasma) or in International Units (IU) (relative to an International Standard for factor VIII in plasma).</p><p>&nbsp;</p><p>One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml normal human plasma.</p><p><em>&nbsp;</em></p><p><em>On-demand treatment</em></p><p>The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dl. The required dose is determined using the following formula:</p><p>&nbsp;</p><p>Required units (IU) = body weight (kg) &times; desired factor VIII rise (%) (IU/dl) &times; 0.5 (IU/kg per IU/dl).</p><p><strong>&nbsp;</strong></p><p>The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.</p><p>&nbsp;</p><p>In case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:</p><p>&nbsp;</p><p><strong>Table 1 Guide for dosing in bleeding episodes and surgery</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:467px"><thead><tr><td style="vertical-align:top"><p><strong>Degree of haemorrhage/Type of surgical procedure</strong></p></td><td style="vertical-align:top"><p><strong>FVIII level required (%) (IU/dl)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of doses (hours)/Duration of therapy (days)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong><em>Haemorrhage</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Early haemarthrosis, muscle bleeding or oral bleeding</p></td><td style="vertical-align:top"><p>20&ndash;40</p></td><td style="vertical-align:top"><p>Repeat every 12&ndash;24 hours, at least 1 day, until the bleeding episode as indicated by pain is resolved or healing achieved</p></td></tr><tr><td style="vertical-align:top"><p>More extensive haemarthrosis, muscle bleeding or haematoma</p></td><td style="vertical-align:top"><p>30&ndash;60</p></td><td style="vertical-align:top"><p>Repeat infusion every 12&ndash;24 hours for 3&ndash;4 days or more until pain and acute disability are resolved</p><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Life threatening haemorrhages</p></td><td style="vertical-align:top"><p>60&ndash;100</p></td><td style="vertical-align:top"><p>Repeat infusion every 8&ndash;24 hours until threat is resolved</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Surgery</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Minor surgery</em></p><p>including tooth extraction</p></td><td style="vertical-align:top"><p>30&ndash;60</p></td><td style="vertical-align:top"><p>Every 24 hours, at least 1 day, until healing is achieved</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Major surgery</em></p></td><td style="vertical-align:top"><p>80&ndash;100</p><p>(pre- and postoperative)</p></td><td style="vertical-align:top"><p>Repeat infusion every 8&ndash;24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30% to 60% (IU/dl)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Prophylaxis</em></p><p>For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual recommended doses are 20&ndash;40 IU of factor VIII per kg body weight every second day or 20&ndash;50 IU of factor VIII per kg body weight 3 times weekly. In adults and adolesents (&gt;12 years) a less frequent regimen (40-60 IU/kg every third day or twice weekly) may be applicable. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.</p><p>&nbsp;</p><p><em>Surgery</em></p><p>There is limited experience of surgery in paediatric patients.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>There is no experience in patients &gt; 65 years.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>For long term prophylaxis against bleeding in patients below the age of 12, doses of 25&ndash;50 IU of factor VIII per kg body weight every second day or 25&ndash;60 IU of factor VIII per kg body weight 3 times weekly are recommended. For paediatric patients above the age of 12 the dose recommendations are the same as for adults.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Intravenous use.</p><p>&nbsp;</p><p>The recommended infusion rate for NovoEight<sup>&reg;</sup> is 1&ndash;2 ml/min. The rate should be determined by the patient&rsquo;s comfort level.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see Instructions on how to use NovoEight<sup>&reg;</sup>.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known allergic reaction to hamster proteins.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Traceability</em></p><p>In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><em>Hypersensitivity</em></p><p>Allergic type hypersensitivity reactions are possible with NovoEight<sup>&reg;</sup>. The product contains traces of hamster proteins, which in some patients may cause allergic reactions. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</p><p>&nbsp;</p><p>In case of shock, standard medical treatment for shock should be implemented.</p><p>&nbsp;</p><p><em>Inhibitors</em></p><p>The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days but continues throughout life although the risk is uncommon.</p><p>&nbsp;</p><p>The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre posing less of a risk of insufficient clinical response than high titre inhibitors.</p><p>&nbsp;</p><p>In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observation and laboratory test. If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitors, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.</p><p>&nbsp;</p><p><em>Cardiovascular event</em></p><p>In patients with existing cardiovascular risk factors, substitiution therapy with FVIII may increase the cardiovascular risk.</p><p>&nbsp;</p><p><em>Catheter-related complications</em></p><p>If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered</p><p>&nbsp;</p><p>It is strongly recommended that every time that NovoEight<sup>&reg;</sup> is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The listed warnings and precautions apply both to adults and children.</p><p>&nbsp;</p><p><u>Excipient related considerations</u></p><p>The medicinal product contains 30.5&nbsp;mg sodium per reconstituted vial, equivalent to 1.5% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions of human coagulation factor VIII (rDNA) products with other medicinal products have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with NovoEight<sup>&reg;</sup>. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breastfeeding is not available. Therefore, factor VIII should be used during pregnancy and lactation only if clearly indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoEight<sup>&reg;</sup> has no influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock).</p><p>&nbsp;</p><p>Very rarely development of antibodies to hamster protein with related hypersensitivity reactions has been observed.</p><p>&nbsp;</p><p>Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with NovoEight<sup>&reg;</sup>. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre is contacted.</p><p><u>&nbsp;</u></p><p><em>Tabulated list of adverse reactions</em></p><p>The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).</p><p>&nbsp;</p><p>Frequencies have been evaluated according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), and not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 2 Frequency of adverse drug reactions in clinical trials</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency<sup>a</sup> in PTPs</strong></p></td><td style="vertical-align:top"><p><strong>Frequency<sup>a</sup> in PUPs</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Uncommon<sup>b</sup></p></td><td style="vertical-align:top"><p>Very common<sup>b</sup></p></td><td style="vertical-align:top"><p>FVIII inhibition</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache, dizziness, burning sensation</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sinus tachycardia, acute myocardial infarction</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension, lymphoedema, hyperaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing, thrombophlebitis superficial</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash, rash erythematous</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, lichenoid keratosis, skin burning sensation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskeletal stiffness, arthropathy, pain in extremity, musculoskeletal pain</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Haemarthrosis, muscle haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common<strong> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reactions<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pyrexia, catheter site erythema</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue, feeling hot, oedema peripheral, pyrexia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic enzymes increased<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anti factor VIII antibody positive</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Heart rate increased</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Incorrect dose administered</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infusion related reaction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Contusion</p></td></tr><tr><td style="vertical-align:top"><p>Product issues</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thrombosis in device</p></td></tr></tbody></table><p><sup>a</sup> Calculated based on total number of unique patients in all clinical trials (301), of which 242 were previously treated patients (PTPs) and 60 were previously untreated patients (PUPs).</p><p><sup>b</sup> Frequency is based on studies with all FVIII products which included patients with severe haemophilia A.</p><p><sup>c</sup> Injection site reactions include injection site erythema, injection site extravasation and injection site pruritus.</p><p><sup>d</sup> Hepatic enzymes increased include alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase and bilirubin.</p><p>&nbsp;</p><p><em>Description of selected adverse reactions</em></p><p>During all clinical studies with NovoEight<sup>&reg;</sup> in previously treated patients, a total of 35 adverse reactions were reported in 23 of 242 patients exposed to NovoEight<sup>&reg;</sup>. The most frequently reported adverse reactions were injection site reactions, incorrect dose administered and hepatic enzymes increased. Of the 35 adverse reactions, 2 were reported in 1 out of 31 patients below 6 years of age, none in patients from 6 to &le; 12 years of age, 1 event in 1 out of 24 patients (12 to &lt; 18 years of age) and 32 were reported in 21 out of 155 adults (&ge; 18 years).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In clinical trials involving 63 previously treated paediatric patients between 0 and 12 years of age and 24 adolescents between 12 and 18 years of age with severe haemophilia A no difference in the safety profile of NovoEight<sup>&reg;</sup> was observed between paediatric patients and adults.</p><p>&nbsp;</p><p>In the trial with previously untreated patients, between 0 and 6 years of age, a total of 46 adverse reactions were reported in 33 of 60 patients exposed to NovoEight<sup>&reg;</sup>. The most frequently reported adverse reaction was Factor VIII inhibition, see section 4.4. High risk genetic mutations were identified in 92.3% of the overall and 93.8% of the high titre confirmed inhibitors. No other factors were significantly associated with inhibitor development.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_23" o:spid="_x0000_s1026"
  type="#_x0000_t202" style='position:absolute;margin-left:77.55pt;
  margin-top:22.6pt;width:6in;height:77.85pt;z-index:-251658752;visibility:visible;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQD3hj+PHAIAABkEAAAOAAAAZHJzL2Uyb0RvYy54bWysU8Fu2zAMvQ/YPwi6L06yJkiNOEWXrsOA
rhvQ7gNoWY6FSaImKbG7rx8lJ2mw3Yb5INAi+fj4SK1vBqPZQfqg0FZ8NplyJq3ARtldxb8/379b
cRYi2AY0WlnxFxn4zebtm3XvSjnHDnUjPSMQG8reVbyL0ZVFEUQnDYQJOmnJ2aI3EOnX74rGQ0/o
Rhfz6XRZ9Ogb51HIEOj2bnTyTcZvWyni17YNMjJdceIW8+nzWaez2Kyh3HlwnRJHGvAPLAwoS0XP
UHcQge29+gvKKOExYBsnAk2BbauEzD1QN7PpH908deBk7oXECe4sU/h/sOLx8M0z1VR8vuTMgqEZ
Pcshsg84sPn7pE/vQklhT44C40D3NOfca3APKH4EZnHbgd3JW++x7yQ0xG+WMouL1BEnJJC6/4IN
1YF9xAw0tN4k8UgORug0p5fzbBIXQZeLq9XyakouQb7r1Wp5vcgloDxlOx/iJ4mGJaPinmaf0eHw
EGJiA+UpJBWzeK+0zvPXlvUEupgvxr5QqyY5U1jwu3qrPTtA2qD8HeuGyzCjIu2xVqbiq3MQlEmN
j7bJVSIoPdrERNujPEmRUZs41AMFJs1qbF5IKI/jvtL7IqND/4uznna14uHnHrzkTH+2JHZa7JPh
T0Z9MsAKSq145Gw0t3F8AHvn1a4j5HGcFm9pIK3KWr2yOPKk/csSHt9KWvDL/xz1+qI3vwEAAP//
AwBQSwMEFAAGAAgAAAAhAFYbTyLhAAAACwEAAA8AAABkcnMvZG93bnJldi54bWxMj8FOwzAQRO9I
/IO1SFxQazcoEEKcClVwQ6gtReXoxkscJbaj2G3Sv2d7gtvO7mj2TbGcbMdOOITGOwmLuQCGrvK6
cbWE3efbLAMWonJadd6hhDMGWJbXV4XKtR/dBk/bWDMKcSFXEkyMfc55qAxaFea+R0e3Hz9YFUkO
NdeDGincdjwR4oFb1Tj6YFSPK4NVuz1aCe2HWW/276vv6o5jW49fYp+dX6W8vZlenoFFnOKfGS74
hA4lMR380enAOtLp4z1ZJSRPKbCLQSQL2hxoytIEeFnw/x3KXwAAAP//AwBQSwECLQAUAAYACAAA
ACEAtoM4kv4AAADhAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQIt
ABQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAAAAAAAAAAAAAAC8BAABfcmVscy8ucmVsc1BLAQIt
ABQABgAIAAAAIQD3hj+PHAIAABkEAAAOAAAAAAAAAAAAAAAAAC4CAABkcnMvZTJvRG9jLnhtbFBL
AQItABQABgAIAAAAIQBWG08i4QAAAAsBAAAPAAAAAAAAAAAAAAAAAHYEAABkcnMvZG93bnJldi54
bWxQSwUGAAAAAAQABADzAAAAhAUAAAAA
" filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.55pt;margin-right:0in;margin-bottom:
     6.0pt;margin-left:7.1pt;line-height:12.6pt;mso-line-height-rule:exactly'><span
     lang=EN-US>The National Pharmacovigilance and Drug Safety Centre (NPC)<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-left:25.1pt;line-height:13.15pt;
     mso-line-height-rule:exactly;tab-stops:28.35pt 43.1pt'><span lang=EN-US
     style='font-family:"Courier New";mso-hansi-font-family:"Times New Roman";
     mso-bidi-font-family:"Times New Roman"'>o<span style='mso-tab-count:1'>  </span></span><span
     lang=EN-US>Fax: +966-11-205-7662<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-left:43.1pt;text-indent:-18.05pt;
     line-height:12.3pt;mso-line-height-rule:exactly;mso-pagination:none;
     mso-list:l1 level1 lfo2;mso-hyphenate:auto;tab-stops:43.1pt 43.15pt;
     text-autospace:none'><![if !supportLists]><span lang=EN-US
     style='mso-bidi-font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
     "Courier New"'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US
     style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:"Verdana",sans-serif;
     mso-hansi-font-family:"Times New Roman"'>SFDA Call Center:<span
     style='letter-spacing:-.15pt'> </span>19999<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;text-indent:-18.05pt;line-height:12.5pt;mso-line-height-rule:
     exactly;mso-pagination:none;mso-list:l1 level1 lfo2;mso-hyphenate:auto;
     tab-stops:43.1pt 43.15pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US>E-mail: <a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
     text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:43.1pt;text-indent:-18.05pt;line-height:13.15pt;
     mso-line-height-rule:exactly;mso-pagination:none;mso-list:l1 level1 lfo2;
     mso-hyphenate:auto;tab-stops:43.1pt 43.15pt;text-autospace:none'><![if !supportLists]><span
     lang=EN-US style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
     mso-fareast-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US>Website: https://ade.sfda.gov.sa<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with recombinant coagulation factor VIII have been reported.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII.</p><p>ATC code: B02BD02.</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>NovoEight<sup>&reg;</sup> contains turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B-domain. This glycoprotein has the same structure as human factor VIII when activated, and post-translational modifications that are similar to those of the plasma-derived molecule. The tyrosine sulphation site present at Tyr1680 (native full length), which is important for the binding to von Willebrand factor, has been found to be fully sulphated in the turoctocog alfa molecule. When infused into a haemophilia patient, factor VIII binds to endogenous von Willebrand factor in the patient&rsquo;s circulation. The factor VIII/von Willebrand factor complex consists of two molecules (factor VIII and von Willebrand factor) with different physiological functions. Activated factor VIII acts as a co-factor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C<em> </em>and<em> </em>results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of bleeding tendencies.</p><p>&nbsp;</p><p>Of note, annualised bleeding rate (ABR) is not comparable between different factor concentrates and between different clinical studies.</p><p>&nbsp;</p><p><strong>Clinical efficacy</strong></p><p>Four multi-centre, open-labelled, non-controlled trials have been conducted to evaluate the safety and efficacy of NovoEight<sup>&reg;</sup> in the prevention and treatment of bleeds and during surgery in patients with severe haemophilia A (factor VIII activity &le; 1%). Three of these trials were performed in previously treated patients and the fourth in previously untreated patients. The trials included 298 exposed patients; 175 adolescents or adult patients without inhibitors from the age of 12 years (&ge; 150 exposure days), 63 previously treated paediatric patients without inhibitors below 12 years of age (&ge; 50 exposure days) and 60 previously untreated patients below 6 years of age. 188 out of 238 previously treated patients continued into the safety extension trial. Treatment with NovoEight<sup>&reg;</sup> was shown to be safe and had the intended haemostatic and preventive effect. Of the 3,293 reported bleeds observed in 298 of the patients, 2,902 (88.1%) of the bleeds were resolved with 1-2 infusions of NovoEight<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>Table 3 Consumption of NovoEight<sup>&reg;</sup> and haemostatic success rates in previously untreated patients (PUP) and previously treated patients (PTP)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Younger children</p><p>(0 &ndash; &lt; 6 years) PUP</p></td><td style="vertical-align:top"><p>Younger children</p><p>(0 &ndash; &lt; 6 years) PTP</p></td><td style="vertical-align:top"><p>Older children</p><p>(6 &ndash; &lt; 12 years) PTP</p></td><td style="vertical-align:top"><p>Adolescents</p><p>(12 &ndash; &lt; 18 years) PTP</p></td><td style="vertical-align:top"><p>Adults</p><p>(&ge; 18 years) PTP</p></td><td style="vertical-align:top"><p>Total</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>298</p></td></tr><tr><td style="vertical-align:top"><p>Dose used for prevention</p><p>per patient (IU/kg BW)</p><p>Mean (SD)</p><p>Min; Max</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>45.2 (14.4)</p><p>4.5; 363.8</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>41.5 (8.1)</p><p>3.4; 196.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>38.4 (9.4)</p><p>3.2; 62.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>28.5 (9.3)</p><p>17.4; 73.9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>28.5 (8.3)</p><p>12.0; 97.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>32.8 (10.9)</p><p>3.2; 363.8</p></td></tr><tr><td style="vertical-align:top"><p>Dose used for treatment of bleed (IU/kg BW)</p><p>Mean (SD)</p><p>Min; Max</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>43.6 (15.2)</p><p>11.9; 118.9</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>44.0 (12.6)</p><p>21.4; 193.8</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>40.4 (10.5)</p><p>24.0; 71.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>29.3 (10.3)</p><p>12.4; 76.8</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>35.0 (12.3)</p><p>6.4; 104.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>37.5 (13.4)</p><p>6.4; 193.8</p></td></tr><tr><td style="vertical-align:top"><p>Success rate<sup>a</sup> %</p></td><td style="vertical-align:top"><p>87.0%</p></td><td style="vertical-align:top"><p>92.2%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.4%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>85.1%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>89.6%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.9%</p><p>&nbsp;</p></td></tr></tbody></table><p>BW: Body weight, SD: Standard deviation</p><p><sup>a</sup> Success is defined as either &#39;Excellent&#39; or &#39;Good&#39;.</p><p>&nbsp;</p><p>Pre-authorisation clinical data were corroborated by a non-interventional, post-authorisation safety study conducted in order to provide additional documentation of the immunogenicity, and efficacy and safety of NovoEight<sup>&reg;</sup> in routine clinical practice. In total 68 previously treated patients (&gt; 150 EDs), of which 14&nbsp;patients were &lt; 12&nbsp;years and 54&nbsp;patients were &ge; 12&nbsp;years, received either on-demand (N=5) or prophylactic (N=63) treatment for a total of 87.8&nbsp;patient years and 8967&nbsp;EDs.</p><p>&nbsp;</p><p><em>Surgery</em></p><p>A total of 30 surgeries were performed in 25 patients of which 26 were major surgeries and 4 were minor. Haemostasis was successful in all surgeries and no treatment failures were reported.</p><p>&nbsp;</p><p>Data on Immune Tolerance Induction (ITI) has been collected in patients with haemophilia A who had developed inhibitors to factor VIII. During clinical trial in PUPs, 21 patients were treated with ITI and 18 (86%) patients completed ITI with a negative inhibitor test result.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>All pharmacokinetic (PK) studies with NovoEight<sup>&reg;</sup> were conducted after i.v. administration of 50&nbsp;IU/kg NovoEight<sup>&reg;</sup> in previously treated patients with severe haemophilia A (FVIII &le; 1%). The analysis of plasma samples was conducted using both the one-stage clotting assay and the chromogenic assay.</p><p>&nbsp;</p><p>The assay performance of NovoEight<sup>&reg;</sup> in FVIII:C assays was evaluated and compared to a marketed full length recombinant FVIII product. The study showed that comparable and consistent results were obtained for both products and that NovoEight<sup>&reg;</sup> can be reliably measured in plasma without the need of a separate NovoEight<sup>&reg;</sup> standard.</p><p>&nbsp;</p><p>The single dose pharmacokinetic parameters of NovoEight<sup>&reg;</sup> are listed in Table 4 for the one-stage clotting assay and in Table 5 for the chromogenic assay.</p><p>&nbsp;</p><p><strong>Table 4 Single-dose pharmacokinetic parameters of NovoEight<sup>&reg;</sup> (50 IU/kg) by age &ndash; one stage clotting assay &ndash; Mean (SD)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:462px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>0 &minus; &lt; 6 years</p></td><td style="vertical-align:top"><p>6 &minus; &lt; 12 years</p></td><td style="vertical-align:top"><p>&ge; 12 years</p></td></tr><tr><td style="vertical-align:top"><p>n=14</p></td><td style="vertical-align:top"><p>n=14</p></td><td style="vertical-align:top"><p>n=33</p></td></tr><tr><td style="vertical-align:top"><p>Incremental recovery (IU/dl)/(IU/kg)</p></td><td style="vertical-align:top"><p>1.8 (0.7)</p></td><td style="vertical-align:top"><p>2.0 (0.4)</p></td><td style="vertical-align:top"><p>2.2 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>AUC ((IU*h)/dl)</p></td><td style="vertical-align:top"><p>992 (411)</p></td><td style="vertical-align:top"><p>1109 (374)</p></td><td style="vertical-align:top"><p>1526 (577)</p></td></tr><tr><td style="vertical-align:top"><p>CL (ml/h/kg)</p></td><td style="vertical-align:top"><p>6.21 (3.66)</p></td><td style="vertical-align:top"><p>5.02 (1.68)</p></td><td style="vertical-align:top"><p>3.63 (1.09)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub> (h)</p></td><td style="vertical-align:top"><p>7.65 (1.84)</p></td><td style="vertical-align:top"><p>8.02 (1.89)</p></td><td style="vertical-align:top"><p>11.00 (4.65)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss</sub> (ml/kg)</p></td><td style="vertical-align:top"><p>56.68 (26.43)</p></td><td style="vertical-align:top"><p>46.82 (10.63)</p></td><td style="vertical-align:top"><p>47.40 (9.21)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (IU/dl)</p></td><td style="vertical-align:top"><p>100 (58)</p></td><td style="vertical-align:top"><p>107 (35)</p></td><td style="vertical-align:top"><p>123 (41)</p></td></tr><tr><td style="vertical-align:top"><p>Mean residence time (h)</p></td><td style="vertical-align:top"><p>9.63 (2.50)</p></td><td style="vertical-align:top"><p>9.91 (2.57)</p></td><td style="vertical-align:top"><p>14.19 (5.08)</p></td></tr></tbody></table><p>Abbreviations: AUC = area under the factor&nbsp;VIII activity time profile; CL = clearance; t<sub>1/2</sub> = terminal half‑life; Vss = volume of distribution at steady-state; C<sub>max</sub> = maximum factor&nbsp;VIII activity.</p><p>&nbsp;</p><p><strong>Table 5 Single-dose pharmacokinetic parameters of NovoEight<sup>&reg; </sup>&nbsp;(50 IU/kg) by age &ndash; chromogenic assay &ndash; Mean (SD)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:464px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Parameter</p></td><td style="vertical-align:top"><p>0 &minus; &lt; 6 years</p></td><td style="vertical-align:top"><p>6 &minus; &lt; 12 years</p></td><td style="vertical-align:top"><p>&ge; 12 years</p></td></tr><tr><td style="vertical-align:top"><p>n=14</p></td><td style="vertical-align:top"><p>n=14</p></td><td style="vertical-align:top"><p>n=33</p></td></tr><tr><td style="vertical-align:top"><p>Incremental recovery (IU/dl)/(IU/kg)</p></td><td style="vertical-align:top"><p>2.2 (0.6)</p></td><td style="vertical-align:top"><p>2.5 (0.6)</p></td><td style="vertical-align:top"><p>2.9 (0.6)</p></td></tr><tr><td style="vertical-align:top"><p>AUC ((IU*h)/dl)</p></td><td style="vertical-align:top"><p>1223 (436)</p></td><td style="vertical-align:top"><p>1437 (348)</p></td><td style="vertical-align:top"><p>1963 (773)</p></td></tr><tr><td style="vertical-align:top"><p>CL (ml/h/kg)</p></td><td style="vertical-align:top"><p>4.59 (1.73)</p></td><td style="vertical-align:top"><p>3.70 (1.00)</p></td><td style="vertical-align:top"><p>2.86 (0.94)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub> (h)</p></td><td style="vertical-align:top"><p>9.99 (1.71)</p></td><td style="vertical-align:top"><p>9.42 (1.52)</p></td><td style="vertical-align:top"><p>11.22 (6.86)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss</sub> (ml/kg)</p></td><td style="vertical-align:top"><p>55.46 (23.53)</p></td><td style="vertical-align:top"><p>41.23 (6.00)</p></td><td style="vertical-align:top"><p>38.18 (10.24)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (IU/dl)</p></td><td style="vertical-align:top"><p>112 (31)</p></td><td style="vertical-align:top"><p>125 (27)</p></td><td style="vertical-align:top"><p>163 (50)</p></td></tr><tr><td style="vertical-align:top"><p>Mean residence time (h)</p></td><td style="vertical-align:top"><p>12.06 (1.90)</p></td><td style="vertical-align:top"><p>11.61 (2.32)</p></td><td style="vertical-align:top"><p>14.54 (5.77)</p></td></tr></tbody></table><p>Abbreviations: AUC = area under the factor&nbsp;VIII activity time profile; CL = clearance; t<sub>1/2</sub> = terminal half‑life; Vss = volume of distribution at steady-state; C<sub>max</sub> = maximum factor&nbsp;VIII activity.</p><p>&nbsp;</p><p>The pharmacokinetic parameters were comparable between paediatric patients below 6 years of age and the paediatric patients from 6 to below 12 years of age. Some variation was observed in the pharmacokinetic parameters of NovoEight<sup>&reg;</sup> between paediatric and adult patients. The higher CL and the shorter t<sub>&frac12;</sub> seen in paediatric patients compared to adult patients with haemophilia A may be due in part to the known higher plasma volume per kilogram body weight in younger patients.</p><p>&nbsp;</p><p>A single dose pharmacokinetic trial (50&nbsp;IU/kg) was performed in 35 haemophilia patients (&ge;18&nbsp;years of age) in different BMI categories. The maximum exposure (C<sub>max</sub>) and the total exposure (AUC) increase with increasing BMI indicating that dose adjustments may be required for underweight (BMI &lt;18.5&nbsp;kg/m<sup>2</sup>) and obese patients (BMI &ge;30&nbsp;kg/m<sup>2</sup>), see section 4.2.</p><p>&nbsp;</p><p><strong>Table 6 Single-dose pharmacokinetic parameters of NovoEight<sup>&reg;</sup> (50&nbsp;IU/kg) by BMI classes<sup>a</sup> &ndash; One-stage clotting assay - Mean (SD)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>PK parameter</p></td><td style="vertical-align:top"><p>Underweight N=5</p></td><td style="vertical-align:top"><p>Normal weight N=7</p></td><td style="vertical-align:top"><p>Overweight N=8</p></td><td style="vertical-align:top"><p>Obese class I N=7</p></td><td style="vertical-align:top"><p>Obese class II/III N=7</p></td></tr><tr><td style="vertical-align:top"><p>Incremental recovery (IU/dl)/(IU/kg)</p></td><td><p>1.7 (0.2)</p></td><td><p>2.0 (0.2)</p></td><td><p>2.4 (0.4)</p></td><td><p>2.3 (0.3)<sup>b</sup></p></td><td><p>2.6 (0.3)</p></td></tr><tr><td style="vertical-align:top"><p>AUC ((IU*h)/dl)</p></td><td style="vertical-align:top"><p>1510 (360)</p></td><td style="vertical-align:top"><p>1920 (610)</p></td><td style="vertical-align:top"><p>1730 (610)</p></td><td style="vertical-align:top"><p>2030 (840)</p></td><td style="vertical-align:top"><p>2350 (590)</p></td></tr><tr><td style="vertical-align:top"><p>CL (ml/h/kg)</p></td><td style="vertical-align:top"><p>3.91 (0.94)</p></td><td style="vertical-align:top"><p>3.20 (1.00)</p></td><td style="vertical-align:top"><p>3.63 (1.24)</p></td><td style="vertical-align:top"><p>3.37 (1.79)</p></td><td style="vertical-align:top"><p>2.51 (0.63)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub> (h)</p></td><td style="vertical-align:top"><p>11.3 (2.0)</p></td><td style="vertical-align:top"><p>11.7 (3.5)</p></td><td style="vertical-align:top"><p>9.4 (2.9)</p></td><td style="vertical-align:top"><p>11.2 (3.5)</p></td><td style="vertical-align:top"><p>11.1 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss </sub>(ml/kg)</p></td><td style="vertical-align:top"><p>56.8 (5.4)</p></td><td style="vertical-align:top"><p>44.8 (6.5)</p></td><td style="vertical-align:top"><p>39.6 (6.0)</p></td><td style="vertical-align:top"><p>42.0 (9.0)</p></td><td style="vertical-align:top"><p>35.0 (4.6)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (IU/dl)</p></td><td style="vertical-align:top"><p>100 (11)</p></td><td style="vertical-align:top"><p>121 (10)</p></td><td style="vertical-align:top"><p>144 (26)</p></td><td style="vertical-align:top"><p>140 (21)</p></td><td style="vertical-align:top"><p>161 (32)</p></td></tr><tr><td style="vertical-align:top"><p>Mean residence time (h)</p></td><td style="vertical-align:top"><p>15.1 (3.0)</p></td><td style="vertical-align:top"><p>15.3 (4.8)</p></td><td style="vertical-align:top"><p>11.9 (3.7)</p></td><td style="vertical-align:top"><p>14.4 (4.6)</p></td><td style="vertical-align:top"><p>14.6 (3.7)</p></td></tr></tbody></table><p><sup>a</sup> BMI groups: Underweight: BMI &lt;18.5&nbsp;kg/m<sup>2</sup>, Normal weight: BMI 18.5-24.9&nbsp;kg/m<sup>2</sup>, Overweight: BMI 25-29.9&nbsp;kg/m<sup>2</sup>, Obese class I: BMI 30-34.9&nbsp;kg/m<sup>2</sup>, Obese class II/III: BMI &ge;35&nbsp;kg/m<sup>2</sup>.</p><p><sup>b</sup> Based on 6 patients only.</p><p>&nbsp;</p><p><strong>Table 7 Single-dose pharmacokinetic parameters of NovoEight<sup>&reg;</sup> (50&nbsp;IU/kg) by BMI classes<sup>a</sup> &ndash; Chromogenic assay - Mean (SD)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>PK parameter</p></td><td style="vertical-align:top"><p>Underweight N=5</p></td><td style="vertical-align:top"><p>Normal weight N=7</p></td><td style="vertical-align:top"><p>Overweight N=9</p></td><td style="vertical-align:top"><p>Obese class I N=7</p></td><td style="vertical-align:top"><p>Obese class II/III N=7</p></td></tr><tr><td style="vertical-align:top"><p>Incremental recovery (IU/dl)/(IU/kg)</p></td><td><p>2.2 (0.4)</p></td><td><p>2.9 (0.3)</p></td><td><p>3.0 (0.5)</p></td><td><p>3.2 (0.5)</p></td><td><p>3.5 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p>AUC ((IU*h)/dl)</p></td><td style="vertical-align:top"><p>1860 (700)</p></td><td style="vertical-align:top"><p>2730 (860)</p></td><td style="vertical-align:top"><p>2310 (1020)</p></td><td style="vertical-align:top"><p>2780 (1210)</p></td><td style="vertical-align:top"><p>3050 (730)</p></td></tr><tr><td style="vertical-align:top"><p>CL (ml/h/kg)</p></td><td style="vertical-align:top"><p>3.28 (0.87)</p></td><td style="vertical-align:top"><p>2.25 (0.73)</p></td><td style="vertical-align:top"><p>2.84 (1.09)</p></td><td style="vertical-align:top"><p>2.58 (1.56)</p></td><td style="vertical-align:top"><p>1.94 (0.52)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub> (h)</p></td><td style="vertical-align:top"><p>11.7 (2.4)</p></td><td style="vertical-align:top"><p>11.5 (3.6)</p></td><td style="vertical-align:top"><p>9.7 (3.4)</p></td><td style="vertical-align:top"><p>10.4 (3.2)</p></td><td style="vertical-align:top"><p>10.5 (2.5)</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss </sub>(ml/kg)</p></td><td style="vertical-align:top"><p>49.1 (10.4)</p></td><td style="vertical-align:top"><p>31.2 (4.5)</p></td><td style="vertical-align:top"><p>31.6 (5.8)</p></td><td style="vertical-align:top"><p>28.9 (5.1)</p></td><td style="vertical-align:top"><p>25.7 (4.0)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (IU/dl)</p></td><td style="vertical-align:top"><p>138 (29)</p></td><td style="vertical-align:top"><p>185 (24)</p></td><td style="vertical-align:top"><p>194 (31)</p></td><td style="vertical-align:top"><p>200 (33)</p></td><td style="vertical-align:top"><p>227 (32)</p></td></tr><tr><td style="vertical-align:top"><p>Mean residence time (h)</p></td><td style="vertical-align:top"><p>15.5 (3.2)</p></td><td style="vertical-align:top"><p>15.2 (4.9)</p></td><td style="vertical-align:top"><p>12.6 (4.8)</p></td><td style="vertical-align:top"><p>13.5 (4.6)</p></td><td style="vertical-align:top"><p>13.9 (3.7)</p></td></tr></tbody></table><p><sup>a</sup> BMI groups: Underweight: BMI &lt;18.5&nbsp;kg/m<sup>2</sup>, Normal weight: BMI 18.5-24.9&nbsp;kg/m<sup>2</sup>, Overweight: BMI 25-29.9&nbsp;kg/m<sup>2</sup>, Obese class I: BMI 30-34.9&nbsp;kg/m<sup>2</sup>, Obese class II/III: BMI &ge;35&nbsp;kg/m<sup>2</sup>.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special concern for humans based on conventional studies of safety pharmacology and repeated dose toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Powder:</em></p><p>Sodium chloride, L-histidine, sucrose, polysorbate 80, L-methionine, calcium chloride dihydrate, sodium hydroxide &nbsp;(for pH adjustment) and hydrochloric acid (for pH adjustment).</p><p><u>&nbsp;</u></p><p><em>Solvent:</em></p><p>Sodium chloride and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Expiry date is stated on the labels and carton after ‘Expiry’.

During the shelf life, the product may be kept at:
•	room temperature (≤ 30°C) for a single period no longer than 9 months
or
•	above room temperature (30°C up to 40°C) for a single period no longer than 3 months.

Once the product has been taken out of the refrigerator, the product must not be returned to the refrigerator. 

Please record the beginning of storage and the storage temperature on the product carton.

After reconstitution:
Chemical and physical in-use stability have been demonstrated for:
•	24 hours stored at 2°C – 8°C
•	4 hours stored at 30°C, for product which has been kept for a single period no longer than 9 months at room temperature (≤ 30°C)
•	4 hours stored up to 40°C, for product which has been kept for a single period no longer than 3 months at above room temperature (30°C up to 40°C). 

From a microbiological point of view, the medicinal product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than as stated above, unless reconstitution has taken place in controlled and validated aseptic conditions.

Any unused reconstituted product stored at room temperature (≤ 30°C) or up to 40°C for more than 4 hours should be discarded.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage at room temperature (&le; 30&deg;C) or up to 40&deg;C and storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each pack of NovoEight<sup>&reg; </sup>250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection contains:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 glass vial (type I) with powder and chlorobutyl rubber stopper</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 sterile vial adapter for reconstitution</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe of 4 ml solvent with backstop (polypropylene), a rubber plunger (bromobutyl) and a syringe cap with a stopper (bromobutyl)</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 plunger rod (polypropylene).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>